Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights| Protein Name | Adhesion G protein-coupled receptor B1 |
| Gene Name | ADGRB1 |
| Uniprot | O14514 (Human); Q3UHD1 (Mouse) |
| Synonym | BAI1; GDAIF; brain-specific angiogenesis inhibitor 1 |
| Background | ADGRB1, also known as adhesion G protein-coupled receptor B1 or brain-specific angiogenesis inhibitor 1 (BAI1), is a protein encoded by the human BAI1 gene. It belongs to the adhesion G protein-coupled receptors family which comprises a group of 33 seven-transmembrane-spanning (7TM) proteins that form the second largest family of GPCRs in human. Studies have shown that ADGRB1 is characterized by the presence of large N-terminal extracellular domains (ECDs) which contain multiple subdomains. |
Creative Biolabs offers comprehensive range of membrane protein products empowers your unique research needs.
| CAT# | Product Name | Expression System | Protein Length | Solubilizing Agents |
| S01YF-1023-KX320 | NativeExtract™ Human ADGRB1 Membrane Protein (Full length, Super Nanodisc) | HEK293 cells | Full length | Native Nanodisc |
| Please for more products or customization | ||||
Ph***ix: Creative Biolabs' ADGRB1 protein is ideal for structural and functional GPCR research.
28/Jul/2023
Ca***an: Seamless customization process with rapid turnaround.
03/Mar/2024
We provide tailored solutions to meet your specific requirements. Please for more services.
ADGRB1 Genome Editing for Therapeutic Correction
Creative Biolabs offers ADGRB1 genome editing services for therapeutic correction. ADGRB1, a critical regulator of angiogenesis and neuronal survival, presents a compelling target for genome editing. By designing guide RNAs complementary to pathogenic splice variants or gain-of-function mutations, genome editing can excise aberrant sequences while preserving wild-type ADGRB1 functionality. Preclinical studies in rodent models of cerebrovascular disorders demonstrate that precise editing of ADGRB1 enhancer regions restores physiological expression levels, mitigating pathological vascular remodeling. Creative Biolabs' proprietary sgRNA optimization platforms enhance editing specificity, minimizing off-target effects—an essential consideration for clinical translation.
ADGRB1 Overexpression in Ischemic Pathologies
Creative Biolabs offers ADGRB1 overexpression services in ischemic pathologies. Adeno-associated virus (AAV) vectors engineered with tissue-specific promoters enable spatially controlled ADGRB1 overexpression in ischemic tissues. For instance, AAV9 variants targeting cerebral endothelia efficiently deliver ADGRB1 cDNA, enhancing post-stroke angiogenesis and blood-brain barrier integrity in non-human primate models. Creative Biolabs' expertise in capsid pseudotyping ensures optimal tropism for vascular or neuronal populations, while codon optimization maximizes transgene expression. This strategy, validated in hypoxia-induced injury paradigms, underscores the therapeutic potential of ADGRB1 upregulation.
siRNA Silencing of ADGRB1 in Oncogenic Microenvironments
Creative Biolabs offers siRNA silencing services. In tumorigenic contexts marked by ADGRB1 overexpression, lipid nanoparticle-encapsulated siRNA achieves targeted transcript knockdown. A recent study in glioblastoma xenografts demonstrated that intravenously administered siRNA selectively silences ADGRB1 in neoplastic vasculature, reducing tumor invasivity by 67%. Creative Biolabs' novel nucleotide modification technologies extend siRNA half-life while evading immune surveillance—a critical advancement for systemic delivery. Collaborative consultation is available to navigate siRNA sequence selection, delivery vehicle optimization, and in vivo validation.
Creative Biolabs offers comprehensive and innovative services to drive the development of ADGRB1 cell therapy. Please for more services.
CAR-T Cells Engineered to Target ADGRB1-Associated Tumor Antigens
Creative Biolabs offers CAR-T cell engineering services. Chimeric antigen receptor (CAR)-T cells directed against ADGRB1-derived neoepitopes exhibit potent cytotoxicity in solid malignancies. By integrating ADGRB1-specific single-chain variable fragments (scFvs) with co-stimulatory domains, second-generation CAR-T constructs induce robust anti-tumor responses in colorectal carcinoma models. Creative Biolabs' lentiviral transduction protocols achieve >90% CAR expression in primary T cells, ensuring consistent therapeutic potency.
ADGRB1-Modulated MSC for Tissue Regeneration
Creative Biolabs offers ADGRB1-modulated MSC services for tissue regeneration. Genetic engineering of MSCs to overexpress ADGRB1 enhances their reparative capacity in degenerative disorders. In murine spinal cord injury models, intrathecally administered ADGRB1-modified MSCs secrete pro-angiogenic factors, accelerating neural circuit regeneration by 40%. Creative Biolabs' electroporation-based transfection systems ensure high-efficiency gene delivery without compromising stem cell viability—a prerequisite for clinical-grade production. Researchers pursuing regenerative therapies may leverage our expertise in MSC characterization, differentiation, or in vivo tracking to expedite preclinical development.
Tissue-Specific Viral Vectors for ADGRB1+ Neural Progenitor Cell Engraftment
Lentiviral vectors encoding ADGRB1 under the control of neural-specific promoters (e.g., Synapsin-1) enable stable transgene expression in progenitor populations. Post-engraftment into Parkinsonian models, these cells exhibit enhanced dopaminergic differentiation and synaptic integration. Creative Biolabs' biosafety-optimized vector systems eliminate recombination risks, ensuring compliance with regulatory standards. Collaborative opportunities exist for custom promoter design, tropism refinement, or efficacy assessment in complex disease models.
From editing to engineered cellular platforms, ADGRB1's multifaceted biology demands tailored strategies. Creative Biolabs' end-to-end solutions—spanning vector design, preclinical validation, and compliant manufacturing—position your research for translational success. Please feel free to to refine your gene or cell therapy pipeline, access proprietary technologies, or design validation studies that align with regulatory benchmarks. Elevate your ADGRB1 program with a partner dedicated to precision, innovation, and clinical impact.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
